---
layout: default
title: Pivmecillinam Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 232
evidence_level: L5
indication_count: 0
---

# Pivmecillinam Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pivmecillinam Hydrochloride: From Urinary Tract Infection — No Repurposing Prediction Available

## One-Sentence Summary

Pivmecillinam hydrochloride is an oral prodrug of mecillinam, a penicillin-class antibiotic classically used to treat uncomplicated urinary tract infections (UTIs) caused by gram-negative bacteria.
The current Evidence Pack **does not contain any TxGNN repurposing predictions** for this drug — the predicted_indications array is empty — so no new indication can be evaluated at this time.
One active registration is confirmed in Malaysia, but licence details and safety data remain incomplete and require remediation before any repurposing analysis can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Urinary tract infections (UTI) — based on pharmacological class; regulatory text unavailable in current pack |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet generated |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as Data Gap DG002). Based on established pharmacology, pivmecillinam hydrochloride is a prodrug that is hydrolysed in vivo to mecillinam. Mecillinam selectively binds penicillin-binding protein 2 (PBP2) in gram-negative bacteria, disrupting cell wall synthesis and causing characteristic spheroplast formation — a mode of action distinct from other beta-lactams that target PBP1 or PBP3. This PBP2 selectivity gives it narrow but potent activity against *Enterobacteriaceae* such as *E. coli*, the dominant uropathogen.

Because TxGNN predictions are absent from this Evidence Pack, no mechanistic bridge between pivmecillinam's known MOA and any candidate new indication can be constructed at this stage. The knowledge-graph traversal and deep-learning scoring steps have either not been run or their outputs were not included in this submission.

A meaningful repurposing rationale will only be possible once: (a) the TxGNN pipeline is executed and `predicted_indications` is populated, and (b) the DrugBank entry is retrieved to confirm MOA, drug categories, and known interactions.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication — TxGNN predictions are not yet available for this drug.

---

## Literature Evidence

Currently no related literature available — a target indication must be identified from TxGNN output before a directed literature search can be conducted.

---

## Malaysia Market Information

The Evidence Pack returns one confirmed registration; however, all structured fields (licence number, product name, dosage form, manufacturer, approved indication text) were returned as empty strings by the NPRA query. The record confirms market presence but is not yet parseable.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|---------------------|
| (Not returned by NPRA query) | (Not returned) | (Not returned) | (Not returned) |

> **Action required**: Re-query NPRA with the full product name or MAL number to retrieve complete licence details, or download the package insert PDF directly from the NPRA portal to recover indication text and warning information.

---

## Safety Considerations

All safety fields in the current Evidence Pack are flagged as gaps. No drug–drug interactions were found in the DDI query (0 results). Until the package insert is retrieved and parsed, no safety summary can be generated.

> Please refer to the package insert for safety information. Two blocking/high-severity data gaps must be resolved before safety evaluation can proceed (see Conclusion below).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for pivmecillinam hydrochloride is structurally incomplete — there are no TxGNN repurposing predictions, no approved indication text from NPRA, and no MOA or safety data — making it impossible to evaluate any new indication with meaningful confidence.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Retrieve the NPRA/TFDA package insert PDF and parse warning language and contraindications; this is a prerequisite for S1 safety screening.
- **[DG002 — High]** Query the DrugBank API using the INN "pivmecillinam" or "mecillinam" to confirm DrugBank ID, drug categories, MOA description, and toxicity data.
- **[Pipeline gap]** Re-run the TxGNN KG + DL prediction pipeline with pivmecillinam as input drug to generate `predicted_indications`; without this output, the repurposing report cannot proceed past this Hold stage.
- **[NPRA gap]** Re-query NPRA with the full product or MAL identifier to populate licence number, product name, dosage form, and approved indication text.
- Once a top predicted indication is returned, initiate a directed ClinicalTrials.gov and PubMed evidence search to determine the true evidence level (L1–L5) and revise the decision recommendation accordingly.

---

*This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

